Literature DB >> 11070015

Resistance of native, oligomeric envelope on simian immunodeficiency virus to digestion by glycosidases.

R E Means1, R C Desrosiers.   

Abstract

Stocks of simian immunodeficiency virus (SIV) from the supernatants of infected cell cultures were used to examine the sensitivity of envelope glycoprotein gp120 to enzymatic deglycosylation and the effects of enzyme treatment on infectivity. Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and Western blot analysis revealed little or no change in the mobility of virion-associated gp120 after digestion with high concentrations of N-glycosidase F, endoglycosidase F, endoglycosidase H, and endo-beta-galactosidase. Soluble gp120, which was not pelletable after the enzymatic reaction, was sensitive to digestion by the same enzymes within the same reaction mix and was only slightly less sensitive than gp120 that had been completely denatured by boiling in the presence of SDS and beta-mercaptoethanol. Digestion by three of the seven glycosidases tested significantly changed the infectivity titer compared to that of mock-treated virus. Digestion by endo-beta-galactosidase increased infectivity titers by about 2.5-fold, and neuraminidase from Newcastle disease virus typically increased infectivity titers by 8-fold. Most or all of the increase in infectivity titer resulting from treatment with neuraminidase could be accounted for by effects on the virus, not the cells; SIV produced in the presence of the sialic acid analog 2,3-dehydro-2-deoxy-N-acetylneuraminic acid also exhibited increased infectivity, and the effects could not be duplicated by neuraminidase treatment of cells. Digestion with mannosidase reduced infectivity by fivefold. Our results indicate that carbohydrates on native oligomeric gp120 as it exists on the surface of virus particles are largely occluded and are refractory to digestion by glycosidases. Furthermore, the sialic acid residues at the ends of carbohydrate side chains significantly reduce the inherent infectivity of SIV.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11070015      PMCID: PMC113208          DOI: 10.1128/jvi.74.23.11181-11190.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Inhibition of human immunodeficiency virus syncytium formation and virus replication by castanospermine.

Authors:  B D Walker; M Kowalski; W C Goh; K Kozarsky; M Krieger; C Rosen; L Rohrschneider; W A Haseltine; J Sodroski
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

2.  Enhanced HIV infectivity and changes in GP120 conformation associated with viral incorporation of human leucocyte antigen class I molecules.

Authors:  A Cosma; D Blanc; J Braun; C Quillent; C Barassi; C Moog; S Klasen; B Spire; G Scarlatti; E Pesenti; A G Siccardi; A Beretta
Journal:  AIDS       Date:  1999-10-22       Impact factor: 4.177

Review 3.  Assembly of asparagine-linked oligosaccharides.

Authors:  R Kornfeld; S Kornfeld
Journal:  Annu Rev Biochem       Date:  1985       Impact factor: 23.643

4.  Antibody-independent, complement-mediated enhancement of HIV-1 infection by mannosidase I and II inhibitors.

Authors:  D C Montefiori; W E Robinson; W M Mitchell
Journal:  Antiviral Res       Date:  1989-04       Impact factor: 5.970

5.  Carbohydrates of human immunodeficiency virus. Structures of oligosaccharides linked to the envelope glycoprotein 120.

Authors:  H Geyer; C Holschbach; G Hunsmann; J Schneider
Journal:  J Biol Chem       Date:  1988-08-25       Impact factor: 5.157

6.  Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1.

Authors:  D C Montefiori; W E Robinson; W M Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

7.  Myxoma virus encodes an alpha2,3-sialyltransferase that enhances virulence.

Authors:  R J Jackson; D F Hall; P J Kerr
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

8.  Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase.

Authors:  R A Gruters; J J Neefjes; M Tersmette; R E de Goede; A Tulp; H G Huisman; F Miedema; H L Ploegh
Journal:  Nature       Date:  1987 Nov 5-11       Impact factor: 49.962

9.  Glycosylation and processing of the human immunodeficiency virus type 1 envelope protein.

Authors:  K Kozarsky; M Penman; L Basiripour; W Haseltine; J Sodroski; M Krieger
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

10.  Role of N-linked glycans in the interaction between the envelope glycoprotein of human immunodeficiency virus and its CD4 cellular receptor. Structural enzymatic analysis.

Authors:  E Fenouillet; B Clerget-Raslain; J C Gluckman; D Guétard; L Montagnier; E Bahraoui
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

View more
  19 in total

1.  HIV-1 virus-like particles bearing pure env trimers expose neutralizing epitopes but occlude nonneutralizing epitopes.

Authors:  Tommy Tong; Ema T Crooks; Keiko Osawa; James M Binley
Journal:  J Virol       Date:  2012-02-01       Impact factor: 5.103

2.  Role of complex carbohydrates in human immunodeficiency virus type 1 infection and resistance to antibody neutralization.

Authors:  James M Binley; Yih-En Andrew Ban; Emma T Crooks; Dirk Eggink; Keiko Osawa; William R Schief; Rogier W Sanders
Journal:  J Virol       Date:  2010-03-24       Impact factor: 5.103

3.  Quantitative Glycomics: A Combined Analytical and Bioinformatics Approach.

Authors:  L Veillon; S Zhou; Y Mechref
Journal:  Methods Enzymol       Date:  2017-01-09       Impact factor: 1.600

4.  Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: implications for structural analyses of gp120-DC-SIGN binding.

Authors:  Patrick W-P Hong; Karen B Flummerfelt; Aymeric de Parseval; Kevin Gurney; John H Elder; Benhur Lee
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  Fundamental difference in the content of high-mannose carbohydrate in the HIV-1 and HIV-2 lineages.

Authors:  Elizabeth Stansell; Ronald C Desrosiers
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

6.  Ability of the V3 loop of simian immunodeficiency virus to serve as a target for antibody-mediated neutralization: correlation of neutralization sensitivity, growth in macrophages, and decreased dependence on CD4.

Authors:  R E Means; T Matthews; J A Hoxie; M H Malim; T Kodama; R C Desrosiers
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

7.  Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus.

Authors:  Eloísa Yuste; Welkin Johnson; George N Pavlakis; Ronald C Desrosiers
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

8.  Glycosylation of gp41 of simian immunodeficiency virus shields epitopes that can be targets for neutralizing antibodies.

Authors:  Eloìsa Yuste; Jacqueline Bixby; Jeffrey Lifson; Shuji Sato; Welkin Johnson; Ronald Desrosiers
Journal:  J Virol       Date:  2008-10-01       Impact factor: 5.103

9.  The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Authors:  Christopher N Scanlan; Ralph Pantophlet; Mark R Wormald; Erica Ollmann Saphire; Robyn Stanfield; Ian A Wilson; Hermann Katinger; Raymond A Dwek; Pauline M Rudd; Dennis R Burton
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

10.  The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120.

Authors:  Rogier W Sanders; Miro Venturi; Linnea Schiffner; Roopa Kalyanaraman; Hermann Katinger; Kenneth O Lloyd; Peter D Kwong; John P Moore
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.